Baxter International (BAX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Mar, 2026Voting matters and shareholder proposals
Election of nine directors is proposed, with all nominees recommended for approval by the board.
Advisory vote on executive compensation for 2025 is recommended for approval.
Ratification of the appointment of the independent registered public accounting firm for 2026 is recommended.
Approval of the Second Amended and Restated 2021 Incentive Plan is recommended.
Amendment to the Certificate of Incorporation to change board size is proposed.
Board of directors and corporate governance
Nine director nominees are listed for election at the annual meeting.
Board recommends all nominees for election.
Proposal to amend the Certificate of Incorporation to adjust board size is included.
Executive compensation and say-on-pay
Advisory vote on named executive officer compensation for 2025 is on the agenda.
Board recommends approval of the executive compensation package.
Latest events from Baxter International
- All five proposals, including director elections and governance changes, passed with strong support.BAX
AGM 20265 May 2026 - Q1 2026 sales up 3% reported, adjusted EPS down 35%, full-year outlook reiterated.BAX
Q1 202630 Apr 2026 - Proposal to amend Board size parameters aims to enhance flexibility and governance.BAX
Proxy filing29 Apr 2026 - Q4 sales up 8% but adjusted EPS down 24%; 2026 outlook flat with margin recovery expected.BAX
Q4 202512 Apr 2026 - Shareholders will vote on key governance, compensation, and board structure changes, all recommended for approval.BAX
Proxy filing23 Mar 2026 - Proxy seeks approval for Board refreshment, pay practices, auditor, and sustainability focus.BAX
Proxy Filing13 Mar 2026 - Oil price exposure halved, new operating model boosts efficiency, and margin recovery expected.BAX
Barclays 28th Annual Global Healthcare Conference11 Mar 2026 - Stable fundamentals, prudent 2026 outlook, and focus on innovation and deleveraging.BAX
Citi’s 2026 Unplugged MedTech and Life Sciences Access Day26 Feb 2026 - Q2 sales and adjusted EPS beat guidance; net loss from goodwill impairment; guidance raised.BAX
Q2 20242 Feb 2026